ECOG-ACRIN Cancer Research Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ECOG-ACRIN Cancer Research Group sits in the top decile of US sponsors by registered trial count (#290 of 15,742 sponsors by registered trial count).
ECOG-ACRIN Cancer Research Group: 75 sponsored US clinical trials, 12 recruiting.
ECOG-ACRIN Cancer Research Group sponsors 75 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 16 completed. 23 of these trials are in Phase 3-4 (later-stage) and 35 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Invasive Breast Carcinoma, with 3 trials.
Top-decile sponsor footprint
ECOG-ACRIN Cancer Research Group ranks in the top decile of sponsors by registered trial count (#290 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 26 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (61.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
75 total, page 2 of 2
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
NCT04527549
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
NCT04438382
Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices
NCT03808818
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab
NCT03412630
Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer
NCT02823652
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
NCT02412670
Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence
NCT01824823
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
NCT02031536
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
NCT01824901
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
NCT01390584
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
NCT01013961
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
NCT01216683
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02085408
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00828009
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
NCT01124695
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT01107626
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
NCT01164228
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer
NCT00316888
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
NCT00309985
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
NCT00303628
Levocarnitine in Treating Fatigue in Cancer Patients
NCT00091169
Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer
NCT00008385
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
NCT00003298
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
NCT00002695
Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed
NCT00002525
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 33 |
| Phase 3 | 23 |
Therapeutic Areas
What is open in the ECOG-ACRIN Cancer Research Group pipeline
12 recruiting of 75 indexed (16% open); 16 completed (21%).
Phase mix: 23 late (III/IV) vs 35 early (I/II) (early-phase heavy).
Top condition: Invasive Breast Carcinoma (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ECOG-ACRIN Cancer Research Group: open-pipeline peers nationwide
Peers matched on 75 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
ECOG-ACRIN Cancer Research Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 75 trials (± recruiting share)
- C. R. Bard · 75 trials · 5% recruiting
- Hartford Hospital · 75 trials · 11% recruiting
- Inova Health Care Services · 75 trials · 29% recruiting
- Ionis Pharmaceuticals · 76 trials · 12% recruiting
Sponsors near 16% open enrollment (± trial volume)
- George Mason University · 16% recruiting · 25 trials
- University of Arizona · 16% recruiting · 349 trials
- University of California, San Francisco · 16% recruiting · 1,713 trials
- University of Oregon · 16% recruiting · 63 trials
Related
What to do with this ECOG-ACRIN Cancer Research Group page
75 registered trials is a research-attention snapshot, not an endorsement of ECOG-ACRIN Cancer Research Group or any single study.
- 12 of ECOG-ACRIN Cancer Research Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Invasive Breast Carcinoma is the condition ECOG-ACRIN Cancer Research Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Invasive Breast Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ECOG-ACRIN Cancer Research Group pipeline card: 75 registered trials from official public datasets.Report a data error.